Claims for Patent: 7,038,071

Summary for Patent: 7,038,071

Title:	Platinum compounds
Abstract:	Platinum compounds, pharmaceutically acceptable salts, and prodrugs thereof. Compositions that include the platinum compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier. Methods for using the platinum compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases.
Inventor(s):	Lal; Manjari (Bellevue, WA)
Assignee:	Sonus Pharmaceuticals, Inc. (Bothell, WA)
Application Number:	10/622,007
Patent Claims:	1. A platinum compound, comprising two dihydrolipoic acid moieties bridged by a platinum atom through dihydrolipoic acid sulfur atoms. 2. The compound of claim 1, wherein the compound is a polynuclear platinum compound. 3. A platinum compound including a moiety having the formula: ##STR00002## wherein X.sub.1 and X.sub.2 are independently selected from chloro, hydroxy, and amino; or pharmaceutically acceptable salts thereof. 4. The compound of claim 3, wherein the compound is a polynuclear platinum compound. 5. A platinum compound having the formula: ##STR00003## wherein X.sub.1 and X.sub.2 are independently selected from chloro, hydroxy, and amino; wherein n is 10 200; or pharmaceutically acceptable salts thereof. 6. The compound of claim 5, wherein n=10 20. 7. The compound of claim 5, wherein n=15. 8. A composition, comprising an amount of a compound of claim 1 effective to treat a proliferative disease in a human or animal subject when administered thereto, together with a pharmaceutically acceptable carrier. 9. The composition of claim 8 further comprising at least one additional agent for the treatment of cancer. 10. The composition of claim 9, wherein the at least one additional agent for the treatment of cancer is selected from flutamide, luprolide, tomoxifen, daunorubicin, fluorouracil, floxuridine, interferon alpha, methotrexate, plicamycin, mecaptopurine, thioguanine, adriamycin, carmustine, lomustine, cytarabine, cyclophosphamide, doxorubicin, estramustine, altretamine, hydroxyurea, ifosfamide, procarbazine, mutamycin, busulfan, mitoxantrone, streptozocin, bleomycin, dactinomycin, idamycin, medroxyprogesterone, estramustine, ethinyl estradiol, estradiol, leuprolide, megestrol, octreotide, diethylstilbestrol, chlorotrianisene, etoposide, podophyllotoxin, goserelin, melphalan, chlorambucil, methlorethamine, thiotepa, betamethasone, dicarbazine, asparaginase, leucovorin, mitotane, vincristine, vinbiastine, and taxanes. 11. A method for treating a cancer disorder in a human or animal subject, comprising administering to the human or animal subject a composition comprising an amount of a compound of claim 1 effective to treat the human or animal subject. 12. The method of claim 11, wherein the composition further comprises at least one additional agent for the treatment of cancer. 13. The method of claim 12, wherein the at least one additional agent for the treatment of cancer is selected from flutamide, luprolide, tomoxifen, daunorubicin, fluorouracil, floxuridine, interferon alpha, methotrexate, plicamycin, mecaptopurine, thioguanine, adriamycin, carmustine, lomustine, cytarabine, cyclophosphamide, doxorubicin, estramustine, altretamine, hydroxyurea, ifosfamide, procarbazine, mutamycin, busulfan, mitoxantrone, streptozocin, bleomycin, dactinomycin, idamycin, medroxyprogesterone, estramustine, ethinyl estradiol, estradiol, leuprolide, megestrol, octreotide, diethylstilbestrol, chlorotrianisene, etoposide, podophyllotoxin, goserelin, melphalan, chlorambucil, methlorethamine, thiotepa, betamethasone, dicarbazine, asparaginase, leucovorin, mitotane, vincristine, vinblastine, and taxanes. 14. The method of claim 11, wherein the cancer is at least one of primary melanoma, metastatic melanoma, thymoma, lymphoma, sarcoma, NSC lung cancer, SC lung cancer, gastric cancer, liver cancer, non-Hodgkin's lymphoma, Hodgkins lymphoma, leukemia, testicular cancer, uterine cancer, cervical cancer, bladder cancer, kidney cancer, colon cancer, colorectal cancer, breast cancer, prostate cancer, ovarian cancer, or pancreatic cancer. 15. A compound of claim 1 for use in the treatment of cancer.

Details for Patent 7,038,071

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2022-07-16